Relationship between glutathione S-transferase P1 (GSTP1), X-ray repair cross complementing group 1 (XRCC1) and 5,10-methylenetetrahydrofolate reductase (5,10-MTHFR) gene polymorphisms and response to chemotherapy in advanced gastric cancer.

IF 0.3 4区医学 Q4 Medicine

Onkologie Pub Date : 2013-01-01 Epub Date: 2013-05-21 DOI:10.1159/000351260

Mei Ji, Bin Xu, Jing-Ting Jiang, Jun Wu, Xiao-Dong Li, Wei-Qing Zhao, Hong-Yu Zhang, Wen-Jie Zhou, Chang-Ping Wu

{"title":"Relationship between glutathione S-transferase P1 (GSTP1), X-ray repair cross complementing group 1 (XRCC1) and 5,10-methylenetetrahydrofolate reductase (5,10-MTHFR) gene polymorphisms and response to chemotherapy in advanced gastric cancer.","authors":"Mei Ji, Bin Xu, Jing-Ting Jiang, Jun Wu, Xiao-Dong Li, Wei-Qing Zhao, Hong-Yu Zhang, Wen-Jie Zhou, Chang-Ping Wu","doi":"10.1159/000351260","DOIUrl":null,"url":null,"abstract":"Background: Our study aimed to investigate the relationship between glutathione S-transferase P1 (GSTP1), 5,10-methylenetetrahydrofolate reductase (5,10-MTHFR) and X-ray repair cross complementing group 1 (XRCC1) gene polymorphisms and the response to chemotherapy in advanced gastric cancer.Patients and methods: 59 cases of advanced gastric cancer were enrolled. All patients were treated with the DCF regimen comprising docetaxel, cisplatin, and 5-fluorouracil. All patients' genotypes regarding GSTP1, XRCC1, and 5,10-MTHFR were analyzed by polymerase chain reaction/ligase detection reaction (PCR-LDR).Results: There were 15 (25.42%) cases of G/G genotype, 21 (35.59%) of G/A genotype, and 23 (38.98%) of A/A genotype for GSTP1, 16 (27.12%) cases of A/A genotype, 18 (30.51%) of G/A genotype, and 25 (42.37%) of G/G genotype for XRCC1, and 21 (35.59%) cases of C/C genotype, 22 (37.29%) of C/T genotype, and 16 (27.12%) of T/T genotype for 5,10-MTHFR. After 2 cycles of chemotherapy, there were 4 cases of complete remission, 14 of partial remission, 19 of stable disease, and 22 of advanced disease, with a total effective rate of 30.51%. Better survival was shown for GSTP1 G/G genotype, XRCC1 A/A genotype, and 5,10-MTHFR T/T genotype (p < 0.05).Conclusion: The gene polymorphisms of GSTP1 G/G, XRCC1 A/A, and 5,10-MTHFR T/T have clinical value for predicting the response to the DCF regimen for advanced gastric cancer.","PeriodicalId":19684,"journal":{"name":"Onkologie","volume":"36 6","pages":"335-40"},"PeriodicalIF":0.3000,"publicationDate":"2013-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1159/000351260","citationCount":"9","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Onkologie","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1159/000351260","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2013/5/21 0:00:00","PubModel":"Epub","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 9

Abstract

Background: Our study aimed to investigate the relationship between glutathione S-transferase P1 (GSTP1), 5,10-methylenetetrahydrofolate reductase (5,10-MTHFR) and X-ray repair cross complementing group 1 (XRCC1) gene polymorphisms and the response to chemotherapy in advanced gastric cancer.

Patients and methods: 59 cases of advanced gastric cancer were enrolled. All patients were treated with the DCF regimen comprising docetaxel, cisplatin, and 5-fluorouracil. All patients' genotypes regarding GSTP1, XRCC1, and 5,10-MTHFR were analyzed by polymerase chain reaction/ligase detection reaction (PCR-LDR).

Results: There were 15 (25.42%) cases of G/G genotype, 21 (35.59%) of G/A genotype, and 23 (38.98%) of A/A genotype for GSTP1, 16 (27.12%) cases of A/A genotype, 18 (30.51%) of G/A genotype, and 25 (42.37%) of G/G genotype for XRCC1, and 21 (35.59%) cases of C/C genotype, 22 (37.29%) of C/T genotype, and 16 (27.12%) of T/T genotype for 5,10-MTHFR. After 2 cycles of chemotherapy, there were 4 cases of complete remission, 14 of partial remission, 19 of stable disease, and 22 of advanced disease, with a total effective rate of 30.51%. Better survival was shown for GSTP1 G/G genotype, XRCC1 A/A genotype, and 5,10-MTHFR T/T genotype (p < 0.05).

Conclusion: The gene polymorphisms of GSTP1 G/G, XRCC1 A/A, and 5,10-MTHFR T/T have clinical value for predicting the response to the DCF regimen for advanced gastric cancer.

查看原文本刊更多论文

谷胱甘肽s -转移酶P1 (GSTP1)、x线修复交叉互补组1 (XRCC1)和5,10-亚甲基四氢叶酸还原酶(5,10- mthfr)基因多态性与晚期胃癌化疗反应的关系

背景:本研究旨在探讨谷胱甘肽s -转移酶P1 (GSTP1)、5,10-亚甲基四氢叶酸还原酶(5,10- mthfr)和x射线修复交叉互补组1 (XRCC1)基因多态性与晚期胃癌化疗反应的关系。患者和方法:59例晚期胃癌患者。所有患者均接受由多西紫杉醇、顺铂和5-氟尿嘧啶组成的DCF方案治疗。采用聚合酶链反应/连接酶检测反应(PCR-LDR)分析所有患者GSTP1、XRCC1和5,10- mthfr基因型。结果:GSTP1有G/G基因型15例(25.42%)、G/A基因型21例(35.59%)、A/A基因型23例(38.98%);XRCC1有A/A基因型16例(27.12%)、G/A基因型18例(30.51%)、G/G基因型25例(42.37%);5,10- mthfr有C/C基因型21例(35.59%)、C/T基因型22例(37.29%)、T/T基因型16例(27.12%)。2个周期化疗后，完全缓解4例，部分缓解14例，病情稳定19例，晚期22例，总有效率30.51%。GSTP1 G/G基因型、XRCC1 A/A基因型和5,10- mthfr T/T基因型患者的生存率较高(p < 0.05)。结论:GSTP1 G/G、XRCC1 A/A、5,10- mthfr T/T基因多态性对预测晚期胃癌DCF方案疗效具有临床价值。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊